ArticleBMJ open2022
Healthcare costs of adverse drug reactions and potentially inappropriate prescribing in older adults: a population-based study.
Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 18 citations in OpenAlex.
- Trial
- Potentially inappropriate prescribing in Iranian elderly population: a nationwide claims-based analysis.BMJ open · 2026Observational
- A Community-Based Cross-Sectional Study to Assess the Prevalence of Polypharmacy and Potentially Inappropriate Medications among Elderly Patients in Urban Areas of Western Rajasthan.Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine · 2026Article
- The Financial and Workforce Impact of Medication Errors in the Finnish Public Healthcare System: A Pilot Study.Health services insights · 2026Article
- Anti-vertigo drug prescribing for patients with vestibular symptoms in primary care: a retrospective observational cohort study.BJGP open · 2025Article
- Prevalence of potentially inappropriate prescribing in community-dwelling older adults: an application of STOPP/START version 3 to The Irish Longitudinal Study on Ageing (TILDA).European geriatric medicine · 2025Article
- Prospective Evaluation of Adverse Drug Reactions in Hospitalized Older Adults in Ethiopia.Journal of personalized medicine · 2025Article
- Economic burden of hospital admissions for adverse drug reactions in France: The IATROSTAT-ECO study.British journal of clinical pharmacology · 2025Article
- Article
- Cost avoidance of pharmacist-led deprescribing using STOPPFrail for older adults in nursing homes.International journal of clinical pharmacy · 2024Article
- Preventability and manageability of adverse drug reactions in COVID-19 with mucormycosis: An observational study.Journal of family medicine and primary care · 2024Article
- Potentially inappropriate prescribing in polymedicated older adults with atrial fibrillation and multimorbidity: a Swedish national register-based cohort study.Frontiers in pharmacology · 2024Article
- A Trial-Based Cost-Utility Analysis of a Medication Optimization Intervention Versus Standard Care in Older Adults.Drugs & aging · 2023Article
- Prevalence and Risk Factors Associated with Potentially Inappropriate Prescribing According to STOPP-2 Criteria among Discharged Older Patients-An Observational Retrospective Study.Pharmaceuticals (Basel, Switzerland) · 2023Article
- An Overview of Clinical Manifestations of Dermatological Disorders in Intensive Care Units: What Should Intensivists Be Aware of?Diagnostics (Basel, Switzerland) · 2023Review
- Sex Differences in Multimorbidity, Inappropriate Medication and Adverse Outcomes of Inpatient Care: MoPIM Cohort Study.International journal of environmental research and public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo describe the distribution of costs based on potentially inappropriate prescribing (PIP) and adverse drug reaction (ADR) status in terms of total direct costs and costs caused by ADRs, among older adults.
designA retrospective cohort study was conducted among older adults, identified from a random sample of the general Swedish population. PIP was identified based on the Screening Tool of Older Persons' Prescriptions (STOPP) criteria and ADRs were identified using the Howard criteria. Causality between PIP and ADRs was evaluated using Hallas' criteria. Prevalence-based direct healthcare costs were calculated for the 3-month study period, including the total cost for healthcare and drugs, and the cost caused by ADRs.
settingAll care levels, including primary care, other outpatient care and inpatient care.
participants813 adults ≥65 years. PRIMARY OUTCOME MEASURES: The prevalence and cost of PIP and ADRs.
resultsTotal direct cost for persons with PIP was approximately twice the total cost of those without PIP (€1958 (€1428-€2616) vs €881 (€817-€1167), p=0.0020). The costs caused by ADRs was 10 times higher among persons with PIP, compared with those without PIP (€270 (€86-€545) vs €27 (€10-€61), p=0.047). For persons with ADRs caused by PIP, total direct costs were €4646 (€2617-€7931). This group represented 8% of the study population and used 25% of the costs. The main cost driver in all studied patient groups was healthcare contacts.
conclusionsOlder persons with PIP and ADRs had high healthcare costs, particularly when ADRs were caused by PIP. Since these costs appear to be substantial, the potential savings by preventing their occurrence may, to a certain degree, cover the added cost of such activities. Further studies should be undertaken to provide further evidence on the costs of PIP, ADRs and ADRs caused by PIP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.